Eli Lilly to Acquire Centessa Pharmaceuticals for $38 per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 07 2026
0mins
Should l Buy CNTA?
Centessa Pharmaceuticals' shares surged 48.11% in pre-market trading, reaching a 52-week high of $40.50.
Eli Lilly has entered into a definitive agreement to acquire Centessa Pharmaceuticals for $38.00 per share in cash, reflecting a strong endorsement of Centessa's promising drug pipeline. Additionally, shareholders will receive a contingent value right that could yield an extra $9.00 per share if certain milestones are met, raising the total potential value to $47.00 per share. This acquisition is expected to enhance the commercialization of Centessa's lead candidate, cleminorexton, which has shown best-in-class potential in clinical trials for narcolepsy.
The acquisition news has generated significant market optimism, driving Centessa's stock price to a new high as investors anticipate the benefits of the deal and the future of its drug development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CNTA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CNTA
Wall Street analysts forecast CNTA stock price to fall
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 39.510
Low
27.00
Averages
38.75
High
62.00
Current: 39.510
Low
27.00
Averages
38.75
High
62.00
About CNTA
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Centessa Pharmaceuticals plc, KORE Group Holdings, Inc., and Clearwater Analytics Holdings, Inc. for potential violations of federal securities laws and breaches of fiduciary duties to shareholders.
- Transaction Details: Centessa Pharmaceuticals is being sold to Eli Lilly for $38.00 per share in cash plus a non-transferrable right worth up to $9.00, KORE Group is selling to Searchlight Capital Partners and Abry Partners for $9.25 per share, while Clearwater Analytics is being sold to Permira and Warburg Pincus for $24.55 per share.
- Shareholder Rights: Halper Sadeh LLC encourages shareholders to contact them to discuss their rights and options at no cost, aiming to secure increased consideration and additional disclosures for shareholders involved in these transactions.
- Legal Support: The firm represents investors globally, focusing on securities fraud and corporate misconduct, having successfully recovered millions for defrauded investors, which underscores their expertise in protecting investor rights.
See More
Honeywell Sells Business to Reshape Portfolio Amid Market Uncertainty
- Honeywell Business Sale: Honeywell sells its Productivity Solutions and Services (PSS) business to Brady Corporation for $1.4 billion in cash, a strategic move to divest cyclical, slower-growing, lower-margin operations, thereby enhancing the overall quality of its portfolio.
- Market Reaction Stable: Despite a 5% rise in oil prices due to uncertainty over commercial shipping traffic in the Strait of Hormuz, the market's decline was less severe than feared, as Treasury yields remained relatively unchanged, indicating a stable investor sentiment.
- Eli Lilly Acquisition Moves: Eli Lilly acquires clinical-stage biotech firm Kelonia Therapeutics for $3.25 billion in cash, aiming to bolster its cancer treatment pipeline, with the deal potentially worth up to $7 billion, showcasing the company's aggressive expansion strategy in oncology.
- Active IPO Market: In spite of uncertainties from the Iran conflict, Jersey Mike's confidentially files for an IPO with a valuation of approximately $8 billion, reflecting ongoing interest in new public offerings and further driving growth in investment banking activities.
See More
Monteverde Law Firm Investigates Multiple Mergers
- Merger Investigations: Monteverde Law Firm is investigating the merger between Wintergreen Acquisition Corp. and KIKA Technology Inc., where KIKA shareholders will receive ordinary shares based on valuation, highlighting the firm's commitment to shareholder rights.
- Cash Acquisition Assurance: Centessa Pharmaceuticals shareholders are expected to receive $38 per share in cash along with a contingent value right worth up to $9, indicating the company's dedication to shareholder compensation and potential future gains.
- Shareholder Voting Schedule: Stellar Bancorp shareholders will vote on May 27, 2026, with expectations of receiving 0.3803 shares of Prosperity common stock and $11.36 in cash per share, reflecting the importance of transparency and shareholder engagement in merger transactions.
- Tender Offer Deadline: Soleno Therapeutics shareholders are expected to receive $53 per share in cash, with the tender offer expiring on May 15, 2026, emphasizing the urgency for shareholders to act to secure their interests.
See More
Eli Lilly to Acquire Kelonia Therapeutics for Up to $7 Billion
- Acquisition Scale: Eli Lilly announced its acquisition of biotech firm Kelonia Therapeutics for up to $7 billion, with $3.25 billion paid upfront and remaining payments contingent on clinical, regulatory, and commercial milestones, expected to close in the second half of 2026.
- Innovative Treatment Technology: Kelonia is developing in vivo CAR-T technology that reprograms patients' T-cells to attack cancer, offering a more convenient alternative to traditional ex vivo methods, potentially transforming treatment for blood cancers and solid tumors.
- Market Competitive Advantage: Lilly plans to leverage Kelonia's technology to expand into hematology, with Van Naarden emphasizing the appeal of a one-time infusion, which could attract more physicians and break the current limitations of treatments confined to academic medical centers.
- Strategic Transformation Direction: Alongside the Kelonia acquisition, Lilly is diversifying its business through multiple acquisitions, such as Centessa Pharmaceuticals and Orna Therapeutics, gradually shifting from being primarily known for GLP-1 drugs for weight loss to a comprehensive biopharmaceutical company covering more therapeutic areas.
See More
Eli Lilly Acquires Centessa Pharmaceuticals for Over $6 Billion
- Acquisition Amount and Market Reaction: Eli Lilly announced the acquisition of Centessa Pharmaceuticals at $38 per share, totaling over $6.3 billion, with a positive market response reflected in a 0.85% stock price increase, indicating investor confidence in the deal.
- Funding Sources and Financial Health: Although specific funding methods were not disclosed, Lilly's $7.2 billion cash reserves and over $42 billion in long-term debt, combined with annual revenues exceeding $65 billion, demonstrate its financial capacity to support the acquisition.
- Drug Development Potential: Centessa's lead drug candidate, cleminorexton, shows promising results in treating sleep disorders and is currently in phase 2a clinical trials, which could provide significant competitive advantages for Lilly if successful.
- Strategic Significance and Future Outlook: This acquisition is part of Lilly's ongoing growth strategy and may drive innovation in the neuroscience field, further solidifying its leadership position in the global pharmaceutical market.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) regarding its sale to Biogen Inc. for $41.00 per share in cash and two contingent value rights of $2.00 each, potentially infringing on shareholder rights.
- Shareholder Rights Protection: The firm encourages Apellis shareholders to understand their legal rights and options, emphasizing free consultations to ensure that shareholder interests are protected in the transaction.
- Additional Company Investigations: Centessa Pharmaceuticals plc (NASDAQ:CNTA) is also under scrutiny for its sale to Eli Lilly for $38.00 per share plus a contingent value right of up to $9.00, with Halper Sadeh LLC investigating possible breaches of fiduciary duties.
- Legal Relief Measures: Halper Sadeh LLC represents investors globally, seeking increased consideration, additional disclosures, or other relief to advocate for the rights of affected shareholders.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Centessa Pharmaceuticals plc, KORE Group Holdings, Inc., and Clearwater Analytics Holdings, Inc. for potential violations of federal securities laws and breaches of fiduciary duties to shareholders.
- Transaction Details: Centessa Pharmaceuticals is being sold to Eli Lilly for $38.00 per share in cash plus a non-transferrable right worth up to $9.00, KORE Group is selling to Searchlight Capital Partners and Abry Partners for $9.25 per share, while Clearwater Analytics is being sold to Permira and Warburg Pincus for $24.55 per share.
- Shareholder Rights: Halper Sadeh LLC encourages shareholders to contact them to discuss their rights and options at no cost, aiming to secure increased consideration and additional disclosures for shareholders involved in these transactions.
- Legal Support: The firm represents investors globally, focusing on securities fraud and corporate misconduct, having successfully recovered millions for defrauded investors, which underscores their expertise in protecting investor rights.
See More
Honeywell Sells Business to Reshape Portfolio Amid Market Uncertainty
- Honeywell Business Sale: Honeywell sells its Productivity Solutions and Services (PSS) business to Brady Corporation for $1.4 billion in cash, a strategic move to divest cyclical, slower-growing, lower-margin operations, thereby enhancing the overall quality of its portfolio.
- Market Reaction Stable: Despite a 5% rise in oil prices due to uncertainty over commercial shipping traffic in the Strait of Hormuz, the market's decline was less severe than feared, as Treasury yields remained relatively unchanged, indicating a stable investor sentiment.
- Eli Lilly Acquisition Moves: Eli Lilly acquires clinical-stage biotech firm Kelonia Therapeutics for $3.25 billion in cash, aiming to bolster its cancer treatment pipeline, with the deal potentially worth up to $7 billion, showcasing the company's aggressive expansion strategy in oncology.
- Active IPO Market: In spite of uncertainties from the Iran conflict, Jersey Mike's confidentially files for an IPO with a valuation of approximately $8 billion, reflecting ongoing interest in new public offerings and further driving growth in investment banking activities.
See More
Monteverde Law Firm Investigates Multiple Mergers
- Merger Investigations: Monteverde Law Firm is investigating the merger between Wintergreen Acquisition Corp. and KIKA Technology Inc., where KIKA shareholders will receive ordinary shares based on valuation, highlighting the firm's commitment to shareholder rights.
- Cash Acquisition Assurance: Centessa Pharmaceuticals shareholders are expected to receive $38 per share in cash along with a contingent value right worth up to $9, indicating the company's dedication to shareholder compensation and potential future gains.
- Shareholder Voting Schedule: Stellar Bancorp shareholders will vote on May 27, 2026, with expectations of receiving 0.3803 shares of Prosperity common stock and $11.36 in cash per share, reflecting the importance of transparency and shareholder engagement in merger transactions.
- Tender Offer Deadline: Soleno Therapeutics shareholders are expected to receive $53 per share in cash, with the tender offer expiring on May 15, 2026, emphasizing the urgency for shareholders to act to secure their interests.
See More
Eli Lilly to Acquire Kelonia Therapeutics for Up to $7 Billion
- Acquisition Scale: Eli Lilly announced its acquisition of biotech firm Kelonia Therapeutics for up to $7 billion, with $3.25 billion paid upfront and remaining payments contingent on clinical, regulatory, and commercial milestones, expected to close in the second half of 2026.
- Innovative Treatment Technology: Kelonia is developing in vivo CAR-T technology that reprograms patients' T-cells to attack cancer, offering a more convenient alternative to traditional ex vivo methods, potentially transforming treatment for blood cancers and solid tumors.
- Market Competitive Advantage: Lilly plans to leverage Kelonia's technology to expand into hematology, with Van Naarden emphasizing the appeal of a one-time infusion, which could attract more physicians and break the current limitations of treatments confined to academic medical centers.
- Strategic Transformation Direction: Alongside the Kelonia acquisition, Lilly is diversifying its business through multiple acquisitions, such as Centessa Pharmaceuticals and Orna Therapeutics, gradually shifting from being primarily known for GLP-1 drugs for weight loss to a comprehensive biopharmaceutical company covering more therapeutic areas.
See More
Eli Lilly Acquires Centessa Pharmaceuticals for Over $6 Billion
- Acquisition Amount and Market Reaction: Eli Lilly announced the acquisition of Centessa Pharmaceuticals at $38 per share, totaling over $6.3 billion, with a positive market response reflected in a 0.85% stock price increase, indicating investor confidence in the deal.
- Funding Sources and Financial Health: Although specific funding methods were not disclosed, Lilly's $7.2 billion cash reserves and over $42 billion in long-term debt, combined with annual revenues exceeding $65 billion, demonstrate its financial capacity to support the acquisition.
- Drug Development Potential: Centessa's lead drug candidate, cleminorexton, shows promising results in treating sleep disorders and is currently in phase 2a clinical trials, which could provide significant competitive advantages for Lilly if successful.
- Strategic Significance and Future Outlook: This acquisition is part of Lilly's ongoing growth strategy and may drive innovation in the neuroscience field, further solidifying its leadership position in the global pharmaceutical market.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) regarding its sale to Biogen Inc. for $41.00 per share in cash and two contingent value rights of $2.00 each, potentially infringing on shareholder rights.
- Shareholder Rights Protection: The firm encourages Apellis shareholders to understand their legal rights and options, emphasizing free consultations to ensure that shareholder interests are protected in the transaction.
- Additional Company Investigations: Centessa Pharmaceuticals plc (NASDAQ:CNTA) is also under scrutiny for its sale to Eli Lilly for $38.00 per share plus a contingent value right of up to $9.00, with Halper Sadeh LLC investigating possible breaches of fiduciary duties.
- Legal Relief Measures: Halper Sadeh LLC represents investors globally, seeking increased consideration, additional disclosures, or other relief to advocate for the rights of affected shareholders.
See More
